Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
Subtype terms (2)
More specific conditions that are subtypes of Bacteremia in the MeSH hierarchy.
- Endotoxemia
55 drugs (26 approved, 29 experimental)
- Hemorrhagic Septicemia
Drugs by status
Approved for this indication (8)
Phase 4 trials (31)
- levofloxacin
- sodium citrate
- heparin
- ceftaroline fosamil
- avibactam
- procaine benzylpenicillin
- bifidobacterium animalis
- ceftazidime
- doxycycline
- dicloxacillin
- ethanol
- tigecycline
- daptomycin
- iodine
- octenidine
- piperacillin
- lidocaine
- epinephrine
- immune globulin (human)
- oritavancin
- teicoplanin
- vancomycin
- oligofructose
- propanolol
- gentamicin
- isopropyl alcohol
- cefuroxime
- trovafloxacin
- clindamycin
- chlorhexidine
- +1 more
Phase 3 trials (24)
Phase 2 trials (5)
Phase 1 trials (1)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (45)
- Forest Laboratories
- Merck
- Cubist
- Pharmacia
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- University of Pennsylvania
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Harvard University
- Henry Ford Health System
- McGill University
- Oakland University
- St. John Health System, Michigan
- Sharp HealthCare
- Thammasat University
- The Baruch Padeh Medical Center, Poriya
- Universidad El Bosque, Bogotá
- Universidad Nacional de Colombia
- University of Melbourne
- University of Santiago de Compostela
- University of Taubate
- University of Bern
- University of Valencia
- University of Zurich
- Satellite Healthcare
- Tel Aviv University
- University of Copenhagen
- University of Modena and Reggio Emilia
- Icahn School of Medicine at Mount Sinai
- University of Freiburg
- Emek Medical Center
- +15 more
Organization Involved with Phase 3 Indications (34)
- The Medicines Company
- Theravance
- Basilea Pharmaceutica
- Pfizer
- Novartis
- Biosynexus Incorporated
- BioWest Therapeutics Inc
- ContraFect
- Entasis Therapeutics
- Sponsor GmbH
- Fundación Pública Andaluza
- National Institutes of Health (NIH)
- UMC Utrecht
- Changi General Hospital
- Cornell University
- Papua New Guinea Institute of Medical Research
- Singapore General Hospital
- University of Pavia
- Utrecht University
- Wayne State University
- University of California, San Diego
- University of Cologne
- Spanish Network for Research in Infectious Diseases
- Hospital Universitario Virgen Macarena
- University of Queensland
- National University of Singapore
- UPEC Paris
- Telethon Institute for Child Health Research
- University of Paris
- University of Western Australia
- +4 more
Organization Involved with Phase 2 Indications (20)
- Bristol-Myers Squibb
- AM-Pharma
- Allergan
- Anderson Clinical Research
- Hoechst Marion Roussel
- Inhibitex
- Intron Biotechnology, Inc.
- Nabi Biopharmaceuticals
- XBiotech, Inc.
- National Institute of Dental and Craniofacial Research (NIDCR)
- Duke University
- Katholieke Universiteit Leuven
- Radboud University
- Seoul National University
- Singapore Clinical Research Institute
- University of Florida
- University of Nebraska
- University of Texas at Houston
- Vicuron Pharmaceuticals
- Johnson and Johnson
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (13)
- Winnipeg Regional Health Authority
- University of Manitoba
- Boston University
- Johns Hopkins University
- Mercy Hospital for Women, Australia
- University of Michigan
- East Carolina University
- Erasmus University Rotterdam
- University Teaching Hospital, Lusaka, Zambia
- Zambia Center for Applied Health Research and Development
- MED XL Inc
- Blue Cross Blue Shield
- Assistance Publique - Hôpitaux de Paris